Guoqing Liu

发表

Development and desensitization therapy of high-response factor VIII inhibitors with severe allergic reaction in a moderate hemophilia A patient

Wenman Wu, Guoqing Liu, Zhenping Chen, 2021, International journal of immunopathology and pharmacology.

A low‐dose immune tolerance induction (ITI) protocol incorporating immunosuppressive agents in haemophilia A children with high‐titre factor VIII inhibitor and poor‐ITI prognostic risk

Guoqing Liu, Zhenping Chen, R. Wu, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Altered brain activity and functional networks in school‐age boys with severe haemophilia A: A resting‐state functional magnetic resonance imaging study

D. Hu, Guoqing Liu, R. Wu, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

Individualised prophylaxis based on personalised target trough FVIII level optimised clinical outcomes in paediatric patients with severe haemophilia A

Guoqing Liu, Zhenping Chen, R. Wu, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

Low‐dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors

Guoqing Liu, Zhenping Chen, R. Wu, 2021, Research and practice in thrombosis and haemostasis.

Low‐dose immune tolerance induction in children with severe hemophilia A with high‐titer inhibitors: Type of factor 8 mutation and outcomes

Guoqing Liu, Zhenping Chen, R. Wu, 2022, Research and practice in thrombosis and haemostasis.

Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A

Guoqing Liu, Zhenping Chen, R. Wu, 2021, Pediatric investigation.

Cost-effectiveness Analysis of Prophylaxis Versus On-demand Treatment for Children With Hemophilia B Without Inhibitors in China.

Guoqing Liu, Zhenping Chen, R. Wu, 2021, Clinical therapeutics.

Eradication of FIX inhibitor in haemophilia B children using low‐dose immune tolerance induction with rituximab‐based immunosuppressive agent(s) in China

Guoqing Liu, Zhenping Chen, R. Wu, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China

Guoqing Liu, Zhenping Chen, R. Wu, 2022, Frontiers in Pediatrics.

F8 gene mutation spectrum in severe hemophilia A with inhibitors: A large cohort data analysis from a single center in China

Guoqing Liu, Zhenping Chen, R. Wu, 2022, Research and practice in thrombosis and haemostasis.

Application of peripherally inserted central catheter in immune tolerance induction treatment of children with hemophilia A and accompanying inhibitors in China.

Guoqing Liu, Zekun Li, Y. Zhen, 2023, Hematology.

Central venous access devices implantation in children with severe hemophilia a: data from the children comprehensive care center of China

Guoqing Liu, Zhenping Chen, Y. Zhen, 2023, Heliyon.

The efficacy of the rituximab-containing rescue-regimen for severe hemophilia A inhibitor children who relapsed following successful immune tolerance induction with rituximab in China.

Guoqing Liu, Zhenping Chen, Zekun Li, 2023, Thrombosis Research.

The efficacy of sequential MMF-rescue-regimen to eradicate inhibitors for refractory severe hemophilia A inhibitor children in China.

Guoqing Liu, Zhenping Chen, Zekun Li, 2023, Thrombosis Research.

Early immune tolerance induction is a unique predictor of favorable outcomes in hemophilia A children with intron 22 inversion and high-responding inhibitors.

Guoqing Liu, Zhenping Chen, Zekun Li, 2023, Thrombosis research.

Nephrotic syndrome in two haemophilia B children with inhibitor under low‐dose immune tolerance induction combined with rituximab‐based immunosuppressant protocol

Guoqing Liu, Zhenping Chen, R. Wu, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.